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ABSTRACT 
Background 
Oral calcium and calcitriol are often prescribed after total thyroidectomy to avoid biochemical 
and/or symptomatic hypocalcemia. We aimed to identify independent perioperative factors which 
correlated with the duration of calcium and / or calcitriol supplementation after total thyroidectomy.     
Methods  
Of 271 eligible patients, 48 (17.7%) required calcium and / or calcitriol supplements on discharge. 
Supplementation was gradually weaned off by one surgeon according to a biweekly algorithm 
based on serum calcium (Ca). Duration of supplementation was calculated from the date of 
operation to the date of ceasing all supplementation without biochemical hypocalcemia (i.e. serum 
adjusted-Ca ≥ 8.44mg/dL). The Cox regression analysis was performed to identify independent 
perioperative factors for duration of supplementation. The best cut-off value for these independent 
factors was determined by the receiver characteristic (ROC) curve. 
Results 
In the multivariate analysis, PTH at skin closure (PTH-SC) (RR = 1.742, 95%CI=1.080–2.810) and 
postoperative day 1 adjusted Ca (Ca-D1) (RR=77.526, 95%CI=3.600–1669.57) were the only two 
independent determinants for shorter duration of ceasing all supplementation. The best cut-off 
values in predicting supplementation ≥ 6 months for PTH-SC and Ca-D1 were 7.08pg/mL 
(sensitivity=100%, specificity=60.5%, PPV=40.0% and NPV=100%) and 7.88mg/dL 
(sensitivity=90.0%, specificity=55.3%, PPV=34.6% and NPV=95.5%), respectively. 
Conclusions 
Both PTH-SC and Ca-D1 were independently associated with the duration of supplementation after 
total thyroidectomy. Almost all patients with PTH-SC ≥ 7.08pg/mL or Ca-D1 ≥ 7.88mg/dL did not 
require supplementation ≥ 6 months whereas about 1/3 of patients with PTH-SC < 7.08pg/mL or 
Ca-D1 < 7.88mg/dL required supplementation ≥ 6 months. 
 3 
INTRODUCTION 
Postoperative hypoparathyroidism leading to hypocalcemia is one of the most frequent morbidities 
following total thyroidectomy with an incidence ranging between 3 – 40%.1 However, because 
potentially life-threatening hypocalcemia does not usually develop until 24 to 48 hours after surgery, 
hypoparathyroidism may delay early hospital discharge.2-4 In order to safely manage postoperative 
hypoparathyroidism / hypocalcemia without unnecessarily prolonging hospital stay, two different 
approaches have often been adopted, namely routine calcium and / or calcitriol supplementation or 
selective supplementation, based on postoperative intact parathyroid hormone (PTH) values.2-4 
Some have advocated the latter approach because PTH testing taken within a few hours of surgery 
could accurately predict clinically-relevant hypocalcemia in the immediate postoperative period.5-10 
However, few studies have focused on its predictive value on persistent / long-term 
hypocalcemia.11-14 Wang et al. evaluated the predictive value of postoperative day 1 PTH (PTH-D1) 
on the need for calcitriol supplementation > 1 month and found that none of the 78 patients with 
PTH-D1 ≥ 5 pg/mL required calcium and calcitriol supplementation lasting > 1 month.14 The 
implication is that those with normal to near-normal postoperative PTH level would have a shorter 
duration or greater chance of ceasing all supplementation than those with low to undetectable initial 
PTH. This information is relevant to clinicians because the process of weaning off supplementation 
in patients with hypoparathyroidism often entails multiple clinic visits and blood tests.11-14 
Therefore, knowing which perioperative factors could predict the duration of supplementation could 
potentially reduce the number / frequency of clinic visits and overall costs. However, to our 
knowledge, few studies have specifically examined the association between perioperative 
biochemical factors and duration or chance of ceasing calcium and / or calcitriol supplementation 
after total thyroidectomy.9-14 We hypothesized the perioperative PTH and adjusted calcium (Ca) (i.e. 
the severity of immediate postoperative hypoparathyroidism) might be associated with the duration 
and the chance of weaning off calcium and / or calcitriol supplementation after a total 
thyroidectomy.
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METHODS AND PATIENTS 
The present study protocol was approved by the local institutional review board. From October 
2010 to December 2011, 316 consecutive patients underwent a total or completion-total 
thyroidectomy. All had PTH at skin closure (PTH-SC) and PTH-D1 taken. To minimize other 
confounders, those with concomitant central selective neck dissection (n=15), active bone disease 
(evident by preoperative bone alkaline phosphatase > 150IU/L) (n=3), incomplete / missing 
postoperative PTH values (n=7) or completion total thyroidectomy (n=20) were excluded. 
Therefore, 271 patients were eligible for analysis.  
Postoperative calcium monitoring, supplementation and follow-up protocol 
All postoperative patients were monitored for hypocalcemia. Ca was checked within 4 hours after 
operation, on the following morning (i.e. on postoperative day 1) (Ca-D1) and every 8-10 hours 
until stabilized. Clinically-significant hypocalcemia was defined by the presence of hypocalcemic 
symptoms and/or postoperative serum Ca dropped < 7.60mg/dL (normal range: 8.44 – 10.20mg/dL). 
Those with clinically-significant hypocalcemia were initially given 2500mg oscal tablets (as 
calcium supplements) and were further given calcitriol 0.50mcg twice daily if >2500mg oscal 
tablets alone failed to maintain normcalcemia. The person prescribing the oral calcium and / or 
calcitriol supplementation was unaware of the PTH results. Patients were discharged from hospital 
and followed up 7-10 days after surgery with serum Ca checked beforehand. Figure 1 shows the 
algorithm for weaning off calcium and / or calcitriol supplementation after discharge. To avoid 
individual variability, one surgeon (BHL) was responsible for weaning off supplementation. As a 
general rule, the calcitriol supplementation was weaned off stepwise before the calcium 
supplementation. To avoid the problem of weaning off supplementation prematurely, serum Ca was 
repeated a week later. Patients on calcium and / or calcitriol supplementation were followed-up 
every 2-3 weeks until all supplementation had been completely weaned off. The same follow-up 
protocol was applied to all patients irrespective of their postoperative PTH levels. Patients no longer 
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on supplementation were followed up every 6-12 monthly. All postoperative patients were followed 
up for 2 years before discharged to their primary care physicians. 
The duration of supplementation (in days) was calculated from the date of primary operation to the 
date when all supplementation had been completely weaned off with biochemical normocalcemia 
(i.e. Ca ≥ 8.44mg/dL) (to convert mg/dL to mmol/L, multiply by 0.25) To ensure that those not 
requiring calcium and / or calcitriol supplementation had really not taken any supplementation 
(such as those who might have taken calcium supplementation from other specialties for other 
indications), a careful manual search of all patients’ medication status in the territory-wide Clinical 
Management System (CMS) was performed. The CMS is a computerized database which captures 
all medication entries of all patients in our locality.15 
Surgical technique 
Surgical techniques had been previously described.16 Any devascularized parathyroid glands were 
immediately minced and auto-implanted to the ipsilateral sternocleidomastoid muscle. All data 
were prospectively recorded. 
Laboratory methods 
Ca and phosphate levels were measured in the hospital laboratory by standard methods using the 
Roche Diagnostics Modular Analytic system (Roche Diagnostics, Indianapolis, IN). PTH level was 
measured by Access® 2 immunoassay system (Beckman Coulter, Brea, CA), and the inter- and 
intra-assay CVs were 5.8 and 4.5%, respectively. The normal range for PTH was 11.3 to 53.8pg/mL 
(to convert pg/mL to pmol/L, multiply by 0.106). Serum 25-hydroxyvitamin D was measured by 
using the electrochemiluminescence immunoassay (Elecsys Vitamin D Total assay), and the inter- 
and intra-assay CVs were 6.2 and 4.8%, respectively. The measuring range was 3.00 – 70.0 ng/mL 
(to convert ng/mL to nmol/L, multiply by 2.496). 
Statistics 
Cox proportional hazards regression was used to evaluate the association between potential 
perioperative parameters and duration of supplementation (or chance of weaning off 
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supplementation) in both univariate and multivariate analyses. Only significant variables in the 
univariate analysis were entered into the multivariate analysis. To improve clinical utility of 
independent continuous variables, the receiver operating characteristic (ROC) curve were 
performed to calculate the best cut-off value for predicting duration of supplementation ≥ 6 months. 
The reason for choosing 6 months was because it is often considered a cut-off for temporary and 
permanent hypoparathyroidism. Test sensitivity = true positive / (true positive + false negative); test 
specificity = true negative / (false positive + true negative); positive predictive value (PPV) = true 
positive / (true positive + false positive); negative predictive value (NPV) = True negative / (false 
negative + true negative). All statistical analyses were conducted using SPSS version 18.0 (SPSS, 
Inc., Chicago, IL, USA). P<0.05 was considered statistically significant. 
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RESULTS 
Table 1 shows the patient baseline characteristics and follow-up data. Two-hundred and seventy-
one patients underwent a total thyroidectomy. On discharge, of the 271 patients who underwent 
total thyroidectomy, 48 (17.7%) required supplementation. Eleven of the 48 patients were started on 
supplementation because of symptoms and of these, 8 had Ca < 7.60mg/dL. Under our weaning 
algorithm, no patient had unexpected symptomatic hypocalcemia over the study period. Those on 
calcium alone had significantly higher PTH-D1 (10.4 vs. 2.8pg/mL, p=0.029), Ca-D0 (8.56 vs. 
8.16mg/dL, p=0.003) and Ca-D1 (8.08 vs. 7.68mg/dL, p=0.004) than those on calcium and 
calcitriol.  
Table 2 shows the univariate analysis for duration of stopping calcium and / or calcitriol 
supplementation. PTH-SC ≥ 7.08pg/mL (p=0.001), PTH-D1 ≥ 9.43pg/mL (p=0.003) and Ca-D1 ≥ 
7.88mg/dL (p=0.001) were significant factors for shorter duration of supplementation. When 
entered as continuous variables, the PTH-SC (RR=1.44, 95%CI: 1.15 – 1.81, p=0.002), PTH-D1 
(RR=1.34, 95%CI: 1.10 – 1.62, p=0.003) and Ca-D1 (RR=69.1, 95%CI: 4.54 – 1054.87, p=0.002) 
were significant factors associated with the duration of supplementation. Table 3 shows the 
multivariate analysis for duration of stopping calcium and / or calcitriol supplementation. When 
entered as continuous variables, PTH-SC (RR = 1.742, 95%CI=1.080 – 2.810, p=0.023) and Ca-D1 
(RR=77.526, 95%CI=3.600 – 1669.57, p=0.005) were the two independent factors for duration of 
supplementation. When the 10 patients on supplementation ≥ 6 months were excluded, PTH-SC and 
Ca-D1 remained significant (RR = 1.245, 95% CI=1.001 – 1.548, p=0.049 and RR=30.886, 
95%CI=1.792 – 532.446, p=0.018, respectively). 
Using the ROC, the best cut-off values in predicting supplementation ≥ 6 months for PTH-SC and 
Ca-D1 were 7.08pg/mL (sensitivity=100%, specificity=60.5%, PPV=40.0% and NPV=100%) and 
7.88mg/dL (sensitivity=90.0%, specificity=55.3%, PPV=34.6% and NPV=95.5%), respectively.  
Table 4a is a summary table between PTH-SC < 7.08pg/mL and ≥ 7.08pg/mL and those requiring 
supplements < 6 months, ≥ 6 months and no supplements. Those with PTH-SC ≥ 7.08pg/mL, the 
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median (range) duration of supplementation was 60 (7 – 126) days whereas those with PTH-SC < 
7.08pg/mL, the duration was 140 (7 – 598) days. Of the 10 patients on supplementation ≥6 months, 
3 patients still required supplementation at last follow-up (511, 556 and 598 days, respectively) 
while the other 7 patients stopped supplementation after 231, 283, 297, 204, 339, 350 and 423 days, 
respectively. No patients with PTH-SC ≥ 7.08pg/mL required supplementation ≥ 6 months. 
Table 4b is a summary table between Ca-D1 < 7.88mg/dL and ≥ 7.88mg/dL and those requiring 
supplements < 6 months, ≥ 6 months and no supplements. Those with Ca-D1 ≥ 7.88mg/dL, the 
median (range) duration of supplementation was 61 (7 – 556) days whereas those with Ca-D1 < 
7.88mg/dL, the duration was 122 (8 – 598) days. Only one patient with Ca-D1 ≥ 7.88 mg/dL 
required supplementation ≥ 6 months. 
Table 5 shows using a combination of PTH-SC and Ca-D1 in predicting the need for 
supplementation for < 6 months and ≥ 6 months. Nine of 17 patients with PTH-SC < 7.08pg/mL 
and Ca-D1 < 7.88mg/dL required supplementation ≥ 6 months. By combining both PTH-SC and 
Ca-D1, the PPV increased to 9/17 (52.9%) while the sensitivity was 14/14 (100%). No patient with 
a combined PTH-SC ≥ 7.08pg/mL and Ca-D1 ≥ 7.88mg/dL required supplementation ≥ 6 months. 
The median duration for this subgroup was 36 (7 – 126) days. By using the formula [0.554* (1.740 
* PTH-SC)] + [4.350 * (77.523 * Ca-D1)] derived from the Cox Regression model in the 
multivariate analysis, the AUC for combined PTH-SC and Ca-D1 was slightly higher than the AUC 
for PTH-SC and Ca-D1 alone (0.955 vs. 0.943 and 0.950, respectively). 
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DISCUSSION 
The proportion of patients requiring calcium and / or calcitriol supplementation to prevent 
biochemical and / or symptomatic hypocalcemia after total thyroidectomy tends to vary and is 
dependent on a multitude of factors including preoperative thyroid function, vitamin D level, 
surgical indications, extent of surgery, underlying metabolic bone disease and individual surgeon’s 
threshold for supplementation.1,5,17 However, even when selective supplementation (as opposed to 
routine) is adopted, up to 40% of patients might require some form of supplementation on hospital 
discharge.1 Our study aimed to examine what perioperative factors or indicators were associated 
with the duration of ceasing all supplementation. By knowing these factors, perhaps, the process of 
weaning off supplementation could become more precise.8,11-14,17-18 Although previous studies have 
examined on this issue,11-14 they did not specifically evaluate the extent of perioperative 
biochemical factors in predicting the duration of supplementation. Furthermore, it was unclear if 
their patients were being weaned off the supplementation with a standardized and intensive follow-
up protocol. 
In our study, 15 patients with concomitant central neck dissection and 3 patients with active bone 
disease were excluded from analysis because they often require prolonged period of 
supplementation irrespective of their residual parathyroid function.11 In the univariate analysis, 
PTH-SC, PTH-D1 and Ca-D1 were significant factors for shorter duration of supplementation. 
Based our results, relative to PTH-SC< 7.08pg/mL, those with PTH ≥ 7.08pg/mL had 3.59 times 
shorter duration of needing supplementation. Similarly, those with PTH-D1 ≥ 9.43pg/mL and Ca-
D1 ≥ 7.88mg/dL had 2.84 and 3.20 times shorter duration of supplementation, respectively. 
However, since PTH and Ca were closely inter-related, a multivariate analysis was performed. In 
the multivariate analysis, both PTH-SC and Ca-D1 turned out as independent predictors for 
duration of supplementation and remained significant even when the 10 patients on 
supplementation ≥ 6 months (i.e. those with possible permanent hypoparathyroidism) were 
excluded. Relative to PTH-SC < 7.08pg/mL, PTH-SC ≥ 7.08pg/mL had 2.87 times shorter duration 
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of supplementation while relative to Ca-D1 < 7.88mg/dL, Ca-D1 ≥ 7.88mg/dL had 2.69 times 
shorter duration of supplementation. These findings concurred to our latter findings that the median 
duration of supplementation for PTH < 7.08pg/mL and ≥ 7.08pg/mL were 140 days and 62 days, 
respectively. Similarly, the median duration for Ca-D1 < 7.88mg/dL and ≥ 7.88mg/dL were 122 
days and 61 days, respectively. In fact, no patients with PTH ≥ 7.08pg/mL and only 1 patient with 
Ca-D1 ≥ 7.88mg/dL required supplementation ≥ 6 months. These findings reconfirmed our initial 
hypothesis that both the severity of immediate hypoparathyroidism (as reflected by PTH-SC) and 
hypocalcemia (by Ca-D1) could predict the duration of needing supplementation. However, these 
findings were not surprising because those with low or near-normal PTH or Ca would be expected 
to have their earlier recovery of parathyroid function and shorter duration of supplementation than 
those with very low or undetectable initial PTH or Ca. After all, most temporary 
hypoparathyroidism is probably a result of transient interruption of parathyroid blood supply and so 
those with less compromised blood supply would be expected to recover sooner. This finding 
concurred to those by other authors.12,13 In the second part of the analysis, we evaluated how 
sensitive and specific these two factors were in predicting supplementation < 6 months (temporary 
hypoparathyroidism) and ≥ 6 months (permanent hypoparathyroidism). We found that both PTH-
SC and Ca-D1 were very sensitive, even though not very specific in predicting supplementation < 6 
and ≥ 6 months. None of the 24 patients with PTH-SC ≥ 7.08pg/mL required supplementation ≥ 6 
months regardless of the level of Ca-D1 and only 1 of the 23 patients with Ca-D1 ≥ 7.88mg/dL 
required supplementation ≥ 6 months. However, it should be noted that the PPV was actually 
relatively low (30-40%) (i.e. those with PTH-SC < 7.08pg/mL or Ca-D1 < 7.88mg/dL did not 
always require calcium and / or calcitriol supplementation ≥ 6 months). In fact, only 10 of 25 
patients with PTH-SC < 7.08pg/mL required supplementation ≥ 6 months and 9 of 26 patients with 
Ca-D1 < 7.88mg/dL required supplementation ≥ 6 months. The implication of these findings was 
that the majority (or at least two thirds) of patients would have normalization of parathyroid 
function to the extent of not needing supplementation in the short- to medium term. These findings 
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concurred to a study which found no patients with PTH-D1 ≥ 5 pg/mL required calcium and 
calcitriol supplementation lasting > 1 month. 14 Interestingly, relative to using PTH-SC or Ca-D1 
alone, combining both PTH-SC and Ca-D1 increased the PPV from 34.6% - 40.0% to 52.9% and 
the AUC from 0.943 – 0.950 to 0.955. Although this finding might be seen as an improvement, the 
incremental clinical significance of this remains uncertain. Perhaps, other factors such as 
parathyroid autotransplantation or presence of ectopic parathyroid glands or rests could potentially 
reduce the chance of long-term supplementation, although the former factor did not turn out 
significant in the univariate analysis and so it was not evaluated.19 
Clinical implications 
Instead of having an intensive biweekly follow-up protocol for all patients taking supplementation 
on discharge (i.e. the blanket approach), our results could be extrapolated for stratifying those 
requiring supplementation on discharge according to PTH-SC and Ca-D1. Since those with PTH > 
7.08pg/mL and / or Ca-D1 > 7.88mg/dL would have a significantly greater chance (>90%) of being 
weaned off all supplementation < 6 months, a more intensive protocol would appear appropriate in 
order to minimize the duration of supplementation. In contrast, since those with PTH < 7.08pg/mL 
and / or Ca-D1 < 7.88mg/dL would have a significantly lesser chance (50-66%) of being 
successfully weaned off supplementation < 6 months, a less intensive follow-up (perhaps, a 1-2 
monthly protocol) would be more appropriate and less troublesome for the patient. 
Despite our findings, we would acknowledge the shortcoming that when the duration of 
supplementation was calculated, for simplicity, we did not make a clear distinction between those 
who were weaned off from calcium only and those who were weaned off from calcium and 
calcitriol. It is known that those taking both calcium and calcitriol have more severe 
hypoparathyroidism than those taking calcium alone and would have taken longer to wean off 
supplementation.12,13 The other shortcoming was the fact that some might think that our algorithm 
of weaning off supplementation was too slow and that might have caused some patients actually 
taking supplements more than and / or for longer than it was necessary. For example, some might 
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view that patients with adjusted Ca between 8.44 to 8.80mg/dL probably could be weaned off 
supplementation rather than waiting until the adjusted Ca > 8.80mg/dL. Nevertheless, it was our 
policy that we would rather slightly “overtreat” biochemical hypocalcemia with supplementation 
than to cause transient symptomatic or biochemical hypocalcemia. We are worried that under-
replacement my lead to deterioration in bone mineral density in the long term, although it remains 
unclear what the long-term consequences are. Also it would have been helpful if our data could be 
further supported by the follow-up or latest postoperative PTH levels and used these to further 
correlate with duration of supplementation. 
 
CONCLUSION 
Our data showed that both PTH-SC and Ca-D1 were independent factors for the duration of 
supplementation or chance of weaning off supplementation. Relative to patients with PTH-SC < 
7.08pg/mL or Ca-D1 < 7.88mg/dL, those with PTH-SC ≥ 7.08pg/mL or Ca-D1 ≥ 7.88mg/dL had at 
least 2 times shorter duration of supplementation. Almost all patients with PTH-SC ≥ 7.08pg/mL or 
Ca-D1 ≥ 7.88mg/dL did not require supplementation ≥ 6 months whereas about 1/3 of patients with 
PTH-SC < 7.08pg/mL or Ca-D1 < 7.88mg/dL required supplementation ≥ 6 months.
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Table 1. Patient baseline characteristics, calcium and calcitriol supplements on discharge and at last 
follow-up 
Characteristics Median / no. of patients Range or % 
Age at operation (years) 51 16 - 87 
Female sex 238 87.8 
Surgical indication / final pathology 
- Graves’ disease / toxic MNG 
- Benign pathology 
- Malignancy 
 
28 
205 
38 
 
10.3 
75.6 
14.0 
No. of parathyroid glands identified 
- None or 1 
- 2 
- 3 
- 4 
 
24 
51 
35 
161 
 
8.9 
18.8 
12.9 
59.4 
Parathyroid glands auto-transplantation 65 24.0 
Preoperative adjusted calcium (mg/dL) 9.16 8.48 – 10.20 
Preoperative 25-OHD level (ng/mL) 12.6 3.0 – 31.4 
PTH at skin closure (PTH-SC) (pg/mL) 30.19 1.9 – 158.49 
PTH on postoperative day 1 (PTH-D1) (pg/mL) 24.53 0.9 – 169.81 
Calcium on postoperative day 1 (Ca-D1) (mg/dL) 2.18 1.78 – 2.49 
Supplementation on discharge 
  - Calcium only 
  - Calcium and calcitriol  
48 
20 
28 
17.7 
7.4 
10.3 
Duration of supplementation (days) 
- Calcium on discharge only (n=20) 
- Calcium and calcitriol on discharge (n=28) 
 
31 
119 
 
7 – 350  
10 – 598 
Duration of temporary supplementation* (days) 
- Calcium on discharge only (n=20) 
- Calcium and calcitriol on discharge (n=18) 
 
23.5 
94.5 
 
7 – 177  
10 – 180  
Duration of follow-up since operation (months) 12.7 6.2 – 20.1 
On supplementation for ≥ 6 months 
  - Calcium only 
  - Calcium and calcitriol 
10 
5 
5 
3.4 
1.7 
1.7 
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Abbreviations: MNG = Multinodular goiter; 25-OHD = 25-hydroxyvitamin D; PTH = intact 
parathyroid hormone.  
* after excluding the ten patients who took supplementation for ≥ 6 months  
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Table 2. An univariate analysis on shorter duration of stopping calcium and / or calcitriol 
supplementation  
 Relative risk (95% confident interval) p-value 
Age at operation (years) 1.00 (0.98 – 1.03) 0.947 
Sex  
- Male 
- Female 
 
1 
1.51 (0.46 – 4.90) 
0.498 
No. of parathyroid glands identified 
- ≤ 2 
- > 3 
 
1 
1.18 (0.83 – 1.67) 
0.356 
Parathyroid autotransplantation 
- No 
- One gland 
- Two glands 
 
1 
0.80 (0.40 – 1.60) 
1.60 (0.46 – 5.51) 
0.543 
Preoperative adjusted Ca (mg/dL) 53.73 (0.53 – 5466.37) 0.091 
Preoperative 25-hydroxyvitamin D (ng/mL) 0.96 (0.86 – 1.09) 0.547 
PTH-SC (pg/mL)# 
- < 7.08 
- ≥ 7.08 
 
1 
3.59 (1.71 – 7.53) 
0.001 
PTH-D1 (pg/mL)# 
- < 9.43 
- ≥ 9.43 
 
1 
2.84 (1.44 – 5.59) 
0.003 
Ca-D0 (mg/dL)# 
- < 8.00 
- ≥ 8.00 
 
1 
1.67 (0.65 – 4.30) 
0.288 
Ca-D1 (mg/dL)# 
- <7.88 
- ≥7.88 
 
1 
3.20 (1.61 – 6.36) 
0.001 
 
# the best-cut off value was determined by using the receiver operating characteristic (ROC) curve  
 16 
Table 3. A multivariate analysis on shorter duration of stopping calcium and / or calcitriol 
supplementation after surgery  
Covariates ß-coefficient Relative risk (95% 
confidence interval) 
p-value 
PTH-SC (pg/mL)# 
- < 7.08 
- ≥ 7.08 
 
 
1.053 
 
1 
2.87 (1.27 – 6.49) 
0.012 
PTH-D1 (pg/mL)# 
- < 9.43 
- ≥ 9.43 
 
 
0.178 
 
1 
1.20 (0.95 – 1.50) 
0.123 
Ca-D1 (mg/dL)# 
- <7.88 
- ≥7.88 
 
 
0.990 
 
1 
2.69 (1.24 – 5.83) 
0.012 
When the 10 patients on supplementation for > 6 months were excluded, both PTH-SC and Ca-D1 
remained significant (RR = 1.245, 95% CI=1.001 – 1.548, p=0.049 and RR=30.886, 
95%CI=1.792 – 532.446, p=0.018, respectively) 
# the best-cut off value was determined by the receiver operating characteristic (ROC) curve  
Abbreviations: PTH-SC = parathyroid hormone at skin closure; PTH-D1 = parathyroid hormone on 
day 1; Ca-D0 = calcium on day 0; Ca-D1 = calcium on day 1 
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Table 4a. A summary table between PTH at time of skin closure (PTH-SC) < 7.08pg/mL and ≥ 
7.08pg/mL and between those on supplements < 6 months, ≥ 6 months and no supplements 
 Supplementation for > 
6 months (n=10) 
Supplementation for 
≤ 6 months (n=38) 
No supplementation 
(n=223) 
PTH-SC < 
7.08pg/mL (n=25) 
10 (TP) 15 (FP) 4 
PTH-SC ≥ 
7.08pg/mL (n=23) 
0 (FN) 23 (TN) 219 
 
Table 4b. A summary table between postoperative day 1 adjusted calcium (Ca-D1) < 7.88mg/dL 
and ≥ 7.88mg/dL and between those on supplements < 6 months, ≥ 6 months and no supplements 
 Supplementation for > 
6 months (n=10) 
Supplementation for 
≤ 6 months (n=38) 
No supplementation 
(n=241) 
Ca-D1 < 7.88 
mg/dL (n=26) 
9 (TP) 17 (FP) 2 
Ca-D1 ≥ 7.88 
mg/mL (n=22) 
1 (FN) 21 (TN) 221 
Abbreviations: TP = true positive; FN = false negative; FP = false positive; TN = true negative
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Table 5. A summary table between combining PTH at skin closure (PTH-SC) and postoperative 
day-1 adjusted calcium (Ca-D1) and those on supplements < 6 months and ≥ 6 months 
 Supplementation for 
> 6 months (n=10) 
Supplementation for ≤ 6 
months (n=38) 
PTH-SC < 7.08pg/mL and Ca-D1 < 
7.88 mg/dL (n=17) 
9 8 
PTH-SC ≥ 7.08pg/mL and Ca-D1 < 
7.88 mg/dL (n=9) 
0 9 
PTH-SC < 7.08pg/mL and Ca-D1 ≥ 
7.88 mg/dL (n=8) 
1 7 
PTH-SC ≥ 7.08pg/mL and Ca-D1 ≥ 
7.88 mg/dL (n=14) 
0 14 
 19 
REFERENCES 
1. Wong KP, Lang BH. (2011) Graves' ophthalmopathy as an indication increased the risk of 
hypoparathyroidism after bilateral thyroidectomy. World J Surg 35:2212-8 
2. Landry CS, Grubbs EG, Hernandez M, Hu MI, Hansen MO, Lee JE, Perrier ND. (2012) 
Predictable criteria for selective, rather than routine, calcium supplementation following 
thyroidectomy. Arch Surg 147:338-44. 
3. Wang TS, Cheung K, Roman SA, Sosa JA. (2011) To supplement or not to supplement: a 
cost-utility analysis of calcium and vitamin D repletion in patients after thyroidectomy. Ann 
Surg Oncol. 18:1293-9. 
4. Bellantone R, Lombardi CP, Raffaelli M, Boscherini M, Alesina PF, De Crea C et al. (2002) 
Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy? 
Surgery 132:1109-13 
5. Lang BH, Yih PC, Ng KK. (2012) A prospective evaluation of quick intraoperative 
parathyroid hormone assay at the time of skin closure in predicting clinically relevant 
hypocalcemia after thyroidectomy. World J Surg 36:1300-6. 
6. Noordzij JP, Lee SL, Bernet VJ, Payne RJ, Cohen SM, McLeod IK et al. (2007) Early 
prediction of hypocalcemia after thyroidectomy using parathyroid hormone: an analysis of 
pooled individual patient data from nine observational studies. J Am Coll Surg. 205:748-54 
7. Lombardi CP, Raffaelli M, Princi P, Santini S, Boscherini M, De Crea C et al. (2004) Early 
prediction of postthyroidectomy hypocalcemia by one single iPTH measurement. Surgery 
136:1236–1241 
8. Raffaelli M, De Crea C, Carrozza C, D'Amato G, Zuppi C, Bellantone R et al. (2012) 
Combining early postoperative parathyroid hormone and serum calcium levels allows for an 
efficacious selective post-thyroidectomy supplementation treatment. World J Surg 36:1307-
13 
 20 
9. Youngwirth L, Benavidez J, Sippel R, Chen H. (2010) Postoperative parathyroid hormone 
testing decreases symptomatic hypocalcemia and associated emergency room visits after 
total thyroidectomy. Surgery 148:841-4; discussion 844-6. 
10. Wiseman JE, Mossanen M, Ituarte PH, Bath JM, Yeh MW. (2010) An algorithm informed 
by the parathyroid hormone level reduces hypocalcemic complications of thyroidectomy. 
World J Surg. 34(3):532-7. 
11. Yano Y, Nagahama M, Sugino K, Ito K, Ito K. (2008) Long-term changes in parathyroid 
function after subtotal thyroidectomy for graves' disease. World J Surg 32:2612-6. 
12. Youngwirth L, Benavidez J, Sippel R, Chen H. (2010) Parathyroid hormone deficiency after 
total thyroidectomy: incidence and time. J Surg Res 163:69-71. 
13. Hermann M, Ott J, Promberger R, Kober F, Karik M, Freissmuth M. et al. (2008) Kinetics 
of serum parathyroid hormone during and after thyroid surgery. Br J Surg 95:1480-7. 
14. Wang TS, Cayo AK, Wilson SD, Yen TW. (2011) The value of postoperative parathyroid 
hormone levels in predicting the need for long-term vitamin D supplementation after total 
thyroidectomy. Ann Surg Oncol 18:777-81. 
15. Wong IO, Chan WS, Choi S, Lo SV, Leung GM. (2006) Moral hazard or realised access to 
care? Empirical observation in Hong Kong. Health Policy 75:251-61 
16. Lang BH, Lo CY. (2005) Total thyroidectomy for mulitnodular goiter in the elderly. Am J 
Surg 190:418-23 
17. Erbil Y, Bozbora A, Ozbey N, Issever H, Aral F, Ozarmagan S, Tezelman S.(2007) 
Predictive value of age and serum parathormone and vitamin d3 levels for postoperative 
hypocalcemia after total thyroidectomy for nontoxic multinodular goiter. Arch Surg. 
142:1182-7 
18. AES Guidelines 06/01 Group. Australian Endocrine Surgeons Guidelines AES06/01. (2007) 
Postoperative parathyroid hormone measurement and early discharge after total 
 21 
thyroidectomy: analysis of Australian data and management recommendations. ANZ J Surg 
77:199-202  
19. Lo CY, Lam KY.(1998) Postoperative hypocalcemia in patients who did or did not undergo 
parathyroid autotransplantation during thyroidectomy: a comparative study. Surgery 
124(6):1081-6; discussion 1086-7 
 22 
ACKNOWLEDGMENT 
None 
 
AUTHORS CONTRIBUTIONS 
BHH Lang was involved in the review of literature, acquisition of data and drafting and completing 
the manuscript. KP Wong was also involved in the review of literature and drafting the manuscript. 
BHH Lang conceived the study, participated in the co-ordination and the acquisition of data and 
helped to draft the manuscript. All authors read and approved the final manuscript. 
 
DISCLOSURE STATEMENT 
Both authors had nothing to disclose. No competing financial interests exist. 
 23 
LEGENDS 
Figure 1 shows the algorithm for weaning off calcium and / or calcitriol supplementation after 
hospital discharge 
 
